nad has been researched along with imeglimin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bolze, S; Fouqueray, P; Hallakou-Bozec, S; Kergoat, M; Moller, DE | 1 |
| Nagamine, J | 1 |
2 other study(ies) available for nad and imeglimin
| Article | Year |
|---|---|
Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action.
Topics: Adenosine Triphosphate; Animals; Calcium; Cyclic ADP-Ribose; Cytokines; Diabetes Mellitus, Type 2; Glucose; Insulin Secretion; Islets of Langerhans; Male; Models, Biological; NAD; Niacinamide; Nicotinamide Phosphoribosyltransferase; Rats, Wistar; Ryanodine Receptor Calcium Release Channel; Sulfonylurea Compounds; Triazines | 2021 |
[Pharmacological profile and clinical efficacy of imeglimin hydrochloride (TWYMEEG
Topics: Diabetes Mellitus, Type 2; Glucose; Humans; Hypoglycemic Agents; NAD; Treatment Outcome | 2023 |